DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Respiratory Distress Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Acute Respiratory Distress Syndrome pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Acute Respiratory Distress Syndrome clinical trials, NDA approvals (if any), and product development activities comprising the technology, Acute Respiratory Distress Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
Key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report
- DelveInsight’s Acute Respiratory Distress Syndrome Pipeline analysis depicts a robust space with 60+ active players working to develop 60+ Acute Respiratory Distress Syndrome pipeline treatment therapies.
- The leading Acute Respiratory Distress Syndrome Companies such as Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others are developing potential drug candidates to improve the Acute Respiratory Distress Syndrome treatment scenario.
- Promising Acute Respiratory Distress Syndrome Pipeline Therapies such as MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), Glenzocimab, Gimsilumab, and others.
- The Acute Respiratory Distress Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome R&D. The Acute Respiratory Distress Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Acute Respiratory Distress Syndrome.
Request a sample and discover the recent breakthroughs and advances in Acute Respiratory Distress Syndrome treatment and get a snapshot of the report @ Acute Respiratory Distress Syndrome Pipeline Outlook
Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of Acute Respiratory Distress Syndrome vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness. Along with medical history and physical examination, tests that help in diagnosis of Acute Respiratory Distress Syndrome are imaging tests, blood tests, and/or echocardiogram. Treatment options for Acute Respiratory Distress Syndrome include mechanical ventilation, fluid management, pharmacological treatment, extracorporeal lung support strategies, and other supportive measures. Gene therapy and stem cell therapy are under clinical investigation for the treatment of Acute Respiratory Distress Syndrome.
Recent Developmental Activities in the Acute Respiratory Distress Syndrome Treatment Landscape
- In February 2021, Athersys announced that it had entered into a cooperation agreement with HEALIOS. The cooperation agreement is intended to reaffirm the mutual commitment to the collaborative development of MultiStem in Japan.
- In March 2021, Partner Therapeutics announced a licensing and collaboration agreement with SIRS Therapeutics and F4 Pharma to support the development of FX-06. This synthetic peptide has a broad spectrum of potential indications.
- In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the US FDA awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.
- In December 2020, The Food and Drug Administration (FDA) granted Fast Track designation to remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19).
- In November 2020, Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L to treat acute respiratory distress syndrome.
- In September 2020, Dimerix was awarded USD 1 million from the Australian Government’s BTB program to support the inclusion of DMX-200 in the REMAP-CAP global study.
- In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for the acute respiratory distress syndrome (ARDS) program. In May 2019, US FDA granted Fast Track designation to MultiStem cell therapy for ARDS.
- In June 2020, Quartesian announced a new partnership with Amyndas Pharmaceuticals for their Phase II clinical study evaluating the efficacy of AMY-101 in COVID-19 patients with acute respiratory distress syndrome (ARDS).
Acute Respiratory Distress Syndrome Emerging Drugs: Profile
- BIO-11006: BioMarck Pharmaceuticals
BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.
MultiStem is an “”off-the-shelf”” stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and Acute Respiratory Distress Syndrome. The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Acute Respiratory Distress Syndrome program.
Acute Respiratory Distress Syndrome Therapeutic Assessment
There are approx. 60+ key companies which are developing the therapies for Acute Respiratory Distress Syndrome pipeline. The Acute Respiratory Distress Syndrome Companies which have their Acute Respiratory Distress Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Athersys.
Learn more about the novel and emerging Acute Respiratory Distress Syndrome therapies report @ Acute Respiratory Distress Syndrome Ongoing Trials Analysis
Scope of the Acute Respiratory Distress Syndrome Pipeline Report
- Coverage- Global
- Acute Respiratory Distress Syndrome Companies- Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others.
- Acute Respiratory Distress Syndrome Pipeline Therapies- MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), Glenzocimab, Gimsilumab, and others.
- Acute Respiratory Distress Syndrome Therapeutics Assessment: Phases, Molecule Type, Route of Administration, Product Type
Table of Content
- Introduction
- Acute Respiratory Distress Syndrome Executive Summary
- Acute Respiratory Distress Syndrome: Overview
- Acute Respiratory Distress Syndrome Pipeline Therapeutics
- Acute Respiratory Distress Syndrome Therapeutic Assessment
- Acute Respiratory Distress Syndrome – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Acute Respiratory Distress Syndrome Collaboration Deals
- Late Stage Products (Phase III)
- Traumakine: Faron Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BIO-11006: BioMarck Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- GEn1E-1124: GEn1E Lifesciences
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- IC 100: ZyVersa Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Acute Respiratory Distress Syndrome Key Companies
- Acute Respiratory Distress Syndrome Key Products
- Acute Respiratory Distress Syndrome- Unmet Needs
- Acute Respiratory Distress Syndrome- Market Drivers and Barriers
- Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
- Acute Respiratory Distress Syndrome Analyst Views
- Acute Respiratory Distress Syndrome Key Companies
- Appendix
Key Questions
Current Treatment Scenario and Acute Respiratory Distress Syndrome Emerging Therapies:
- How many companies are developing Acute Respiratory Distress Syndrome drugs?
- How many Acute Respiratory Distress Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Respiratory Distress Syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Respiratory Distress Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Dive deep into rich insights into new Acute Respiratory Distress Syndrome Clinical trials, drugs, and therapies @ Acute Respiratory Distress Syndrome Treatment Landscape
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
